The atypical antipsychotics (Risperdal through Abilify, Fanapt and Saphris) have a safer side effect profile than the typicals (Thorazine through Haldol) in that they have half the statistical potential of causing tardive dyskinesia (a long term side effect which is a movement
disorder of all current antipsychotics except
for Clozaril). They also have far more of a
mood stabilization effect and have been specifically FDA approved for this purpose.